目的 研究丁苯酞注射液联合阿托伐他汀强化治疗急性进展性脑梗死的临床应用效果。方法? 选取江苏大学附属常州市武进人民医院 2018 年 2 月至 2020 年 1 月收治的 100 例急性进展性脑梗死患者作为研究对象，采用随机数字表法分为对照组（50 例）与试验组（50 例）。对照组患者给予阿托伐他汀钙片治疗，试验组患者在对照组的基础上联合丁苯酞氯化钠注射液治疗，两组患者均持续治疗 14 d。比较两组患者治疗后的临床疗效，以及治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分、日常生活活动能力量表（BI）指数及血清凝血酶时间（APTT）、凝血酶原时间（PT）、纤维蛋白原（FIB）水平变化和治疗期间的不良反应发生率。结果? 试验组患者的临床治疗总有效率为 94.00%，显著高于对照组的 80.00%；两组患者治疗后的 NIHSS 评分及血清 FIB 水平均较治疗前有所降低，且试验组数值更低于对照组；而治疗后的 BI 指数及血清 APTT、PT 水平均较治疗前有所升高，且试验组数值更高于对照组；治疗后试验组患者恶心、发热、头部不适等不良反应发生率为 8.00%，显著低于对照组的 26.00%，组间比较差异均有统计学意义（P ＜ 0.05）。结论? 丁苯酞注射液联合阿托伐他汀治疗急性进展性脑梗死患者，可显著提高其临床疗效，改善患者的神经功能及凝血功能，且有效降低不良反应的发生率，临床应用安全有效。
Objective? To study the clinical application of bubphthalide injection combined with atorvastatin in the treatment of acute progressive cerebral infarction. Methods? A total of 100 patients with acute progressive cerebral infarction admitted to Changzhou Wujin People's Hospital Affiliated to Jiangsu University from February 2018 to January 2020 were selected as the research objects，and were divided into a control group and a experimental group by random number table method，with 50 patients in each group. The control group was treated with atorvastatin calcium tablets，the patients in the experimental group were treated with buphthalein chloride injection on the basis of the treatment of the control group，and the two groups were treated for 14 days. The clinical efficacy of the two groups was compared. The NIHSS score，BI index，the levels of APTT，PT and FIB were compared before and after treatment，and the incidence of adverse reactions was observed. Results? The total effective rate of clinical treatment in the experimental group was 94.00%，significantly higher than that in the control group（80.00%）. The NIHSS score and serum FIB level of the two groups after treatment were both lower than that before treatment，and the experimental group was lower than the control group. The BI index，serum APTT and PT levels after treatment were higher than those before treatment，and the values of the experimental group were higher than those of the control group. After treatment，the incidence of adverse reactions such as nausea，fever and head discomfort in the experimental group was 8.00%，significantly lower than that in the control group 26.00%，with statistically significant differences between groups（P＜0.05）. Conclusion? The combination of bubphthalide injection and atorvastatin in the treatment of acute progressive cerebral infarction can significantly improve the clinical efficacy，improve the function of nerve and coagulation，and effectively reduce the incidence of adverse reactions，clinical application is safe and effective.